Advertisement
Takeda Canada Inks Contract With Canadian Blood Services For GLASSIA
(RTTNews) - Takeda Canada Inc., the Canadian arm of Japan's Takeda Pharmaceutical Co. Ltd. (TAK) on Wednesday entered into a contract with Canadian Blood Services (CBS) for GLASSIA (alpha-1 proteinase inhibitor) resulting from CBS's request for proposal for hereditary deficiency of Alpha-1 Antitrypsin Deficiency (Alpha-1).
Glassia has been approved to be listed on the CBS Plasma Protein and Related Products (PPRP) formulary with specific criteria for reimbursement. This marks Takeda's entry into the Alpha-1 community in Canada, building on the company's commitment to developing innovative treatments for rare diseases.
Glassia is a liquid medicine for infusion containing human Alpha 1-Proteinase Inhibitor (A1-PI) also known as alpha-1 antitrypsin (A1AT), which is purified from human blood.
read more
Takeda Says FDA Approves EOHILIA To Treat Eosinophilic Esophagitis
Japan's Takeda Pharmaceutical Co. Ltd. (TAK) announced Monday that the U.S. Food and Drug Administration (FDA) has approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE)1 It will be available in 2 mg/10 mL convenient, single-dose stick packs by the end of February.
RTTNews
|
548 दिनों पहले
Takeda Says Japan Approves CUVITRU Subcutaneous Immunoglobulin For Patients With Agammaglobulinemia
Takeda Pharmaceutical Co. Ltd. (TAK) announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] in patients aged 2 years and older with agammaglobulinemia or hypogammaglobulinemia disorders.
RTTNews
|
688 दिनों पहले
Takeda Says FDA Accepts BLA For ENTYVIO For Maintenance Therapy In Crohn's Disease
Takeda Pharmaceutical Co. Ltd. (TAK) announced Wednesday that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA) for the investigational subcutaneous (SC) administration of ENTYVIO (vedolizumab) for maintenance therapy in adults with moderately to severely active Crohn's disease (CD) after induction therapy with ENTYVIO intravenous (IV).
RTTNews
|
700 दिनों पहले
Takeda Reports Positive Topline Results Of Phase 2b Study Of TAK-279 For Active Psoriatic Arthritis
Takeda Pharmaceutical Co. Ltd. (TAK, TKPHF.PK) announced Monday positive topline results from its randomized, double-blind, placebo-controlled, multiple-dose Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor with next generation selectivity, in people with active psoriatic arthritis.
RTTNews
|
702 दिनों पहले
European Economic News Preview: UK GDP & Foreign Trade Data Due
Monthly GDP estimates and foreign trade from the UK and flash quarterly national accounts and employment from the euro area are due on Thursday. At 2.00 am ET, the Office for National Statistics releases UK GDP, industrial output and foreign trade data. The economy is forecast to grow 0.2 percent on a monthly basis in June, reversing a 0.1 percent fall in May.
RTTNews
|
17 मिनटों पहले
Yen Rises Against Majors
The Japanese yen strengthened against other major currencies in the Asian session on Thursday.
RTTNews
|
27 मिनटों पहले
Sensex, Nifty Marginally Higher Ahead Of US-Russia Talks
Indian shares were marginally higher in early trade on Thursday, mirroring mostly positive cues from global markets ahead of the August 15 meeting between the U.S. President Donald Trump and his Russian counterpart Vladimir Putin.
RTTNews
|
1घंटे 7 मिनट पहले
Australian Market Extends Early Gains In Mid-market
The Australian market is extending early gains in mid-market moves on Thursday, reversing the losses in the previous session, following the broadly positive cues from Wall Street overnight. The benchmark S&P/ASX 200 is moving up to near the 8,900 level to fresh all-time highs, with gains in mining, energy and financial stocks.
RTTNews
|
1घंटे 56 मिनट पहले
